The Canada Atopic Dermatitis Drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Atomic Dermatitis (AD) is a chronic inflammatory skin condition marked by periods of flare (i.e. dry, red, itchy skin that can crack, ooze, and bleed) and periods of remission or disease improvement. The symptoms can lead to lack of sleep, low self-esteem and cause a significant negative impact on quality of life. It is estimated that 11% of children and 7% of adults live with the disease in Canada. Eczema Society ofCanada (ESC) surveyed patients and caregivers and revealed some key challenges Canadians face. 41% of adults with AD are in a constant state of flare. They may experience some improvement of their symptoms but never experience periods of fully clear skin. Nearly half (48%) of adults with AD have experienced an eczema flare 'crisis' that required immediate medical intervention. Timing to see a specialist during a flare is a challenge, with 37% of adult patients and 42% of caregivers worrying they won't see their health care provider during an eczema flare.



Market Drivers

The market is anticipated to progress at a modest pace through the forecast period. The launch of more biologics & small molecules, premium-priced drugs replacing the generic first line and second-line therapeutics, growing incidence of AD, and improved diagnostics are estimated to stoke the market's growth. The rise in awareness regarding the availability of treatments for the disease has helped the market gain traction over the past few years. Initiatives undertaken by governments to provide better and more affordable treatment and the presence of favourable reimbursement policies are likely to provide an upthrust to the market. Furthermore, the growing acceptance of targeted therapies such as Eucrisa and Dupixent also favours the market.